# US 2025/0144147 A1 · Base editing and crispr/cas9 gene editing strategies to correct cd3 severe combined immunodeficiency in hematopoietic stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144147 A1
- Document ID: US20250144147A1
- Status: Published application
- Kind: A1
- Application number: 18/832,890
- Filed: 2023-01-27
- Published: 2025-05-08
- Earliest claimed: 2022-01-27
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Donald B. KOHN; Grace MCAULEY
- Web page: https://patentgrep.com/patent/US20250144147A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- C12N 15/102: {Mutagenizing nucleic acids}
- A61P 37/04: Immunostimulants
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/86: Viral vectors
- C12N 15/907: {in mammalian cells}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2320/34: Allele or polymorphism specific uses
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2830/48: regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are compositions, systems, and methods to provide two gene editing-based approaches that can be used to correct the CD35 SCID-causing C202T mutation (TGA→CGA). In certain embodiments one approach involves CRISPR/Cas9 homology-directed repair (HDR)-mediated correction with a single-strand oligodeoxynucleotide (ssODN) homologous donor. In certain embodiments another approach comprises Adenine Base Editing (ABE)-correction, to precisely revert the CD35 SCID-causing C202T mutation (TGA→CGA).

## Claims

### Claim 1

A system for homology-directed repair (HDR)-mediated correction of the C202T mutation that produces CD3δ SCID disease, said system comprising:
a first single-guide RNA (sgRNA) that directs Cas9 cutting upstream of the C2020T mutation;
a second single-guide RNA (sgRNA) that directs Cas9 cutting downstream of the C2020T mutation; and
a single-strand oligodeoxynucleotide (ssODN) homologous donor comprising a nucleotide sequence that corrects the C202T mutation.

### Claim 2 (depends on 1)

The system of claim 1, wherein said first single-guide RNA comprises a nucleotide sequence that directs Cas9 cutting two base pairs (bp) upstream C202T mutation or wherein said second single-guide RNA comprises a nucleotide sequence that directs Cas9 cutting five bp downstream of the C202T mutation or a combination thereof.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The system according to claim 1, wherein said ssODN is complementary to the nontarget strand with asymmetric homology arms, and optionally wherein said asymmetric homology arms extend 33 bp downstream and 60 bp upstream of the respective sgRNA-guided Cas9 cut site; or said ssODN further comprises a silent PAM mutation to prevent continual nuclease activity; or a combination thereof.

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The system according to claim 1, wherein said system comprises a CRISPR protein or a nucleic acid encoding the CRISPR protein, or a CRISPR/cas9 protein or a nucleic acid encoding the CRISPR/cas9 protein.

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The system according to claim 1, wherein said system is provided as kit comprising one or more containers containing:
said first single-guide RNA (sgRNA);
said second single-guide RNA (sgRNA); and
said single-strand oligodeoxynucleotide (ssODN); wherein said kit optionally comprises a container containing a CRISPR protein or a nucleic acid encoding a CRISPR protein or a CRISPR/Cas9 protein or a nucleic acid encoding the CRISPR/Cas9 protein.

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 1)

A method of correcting a C202T mutation in a mammalian cell using homology-directed repair, said method comprising:
introducing a CRISPR protein, or a nucleic acid comprising the CRISPR protein, or a CRISPR/Cas9 protein, or a nucleic acid comprising the CRISPR/Cas9 protein, and the system according to claim 1 into said cell; and
culturing said cell to permit homology-directed repair (HDR-mediated correction) of the C202T mutation in said cell to provide a corrected cell; wherein said cell is from a human subject identified as having CD3δ severe combined immunodeficiency (SCID).

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21 (depends on 16)

The method according to claim 16, wherein the cell is a stem/progenitor cell, wherein optionally said stem cell is derived from bone marrow, and/or from umbilical cord blood, and/or from peripheral blood, or said progenitor cell is a human hematopoietic progenitor cell.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26 (depends on 16)

The method according to claim 16, wherein said method further comprises introducing said corrected cell into a subject identified as having CD3δ severe combined immunodeficiency (SCID).

### Claim 27

(canceled)

### Claim 28 (depends on 16)

A method of treating a human subject for CD3δ severe combined immunodeficiency (SCID), said method comprising:
providing stem/progenitor cells from said subject;
correcting a C202T mutation in said cells ex vivo using the method according to claim 16 to produce corrected cells; and
introducing said corrected cells into said subject.

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

An adenosine base editor, wherein said base editor is a variant of the wildtype NGG-recognizing Cas9 (D10A) nickase (Cas9n) comprising a combination of amino acid substitutions selected from the group consisting of:
(1) NRTH-ABE8e: A10T, I322V, S409I, E427G, R654L, R753G, R1114G, D1135N, D1180G, G1218S, E1219V, Q1221H, P1249S, E1253K, P1321S, D1332G, and R1335L;
(2) VRER-ABE8e: D1135V, G1218R, R1335E, and T1337R; and
(3) A262T, R324L, S409I, E480K, E543D, M694I, and E1219V.

### Claim 35

(canceled)

### Claim 36 (depends on 34)

The base editor of claim 34, wherein
when said editor comprises the combination of amino acid substitutions: A10T, I322V, S409I, E427G, R654L, R753G, R1114G, D1135N, D1180G, G1218S, E1219V, Q1221H, P1249S, E1253K, P1321S, D1332G, and R1335L, said base editor comprises the amino acid sequence of SEQ ID NO:4 or is encoded by the nucleic acid sequence of SEQ ID NO:3; or
when said editor comprises the combination of amino acid substitutions: D1135V, G1218R, R1335E, and T1337R, said base editor comprises the amino acid sequence of SEQ ID NO:6 or is encoded by the nucleic acid sequence of SEQ ID NO:5; or
when said editor comprises the combination of amino acid substitutions: A262T, R324L, S409I, E480K, E543D, M694I, and E1219V, said base editor comprises the amino acid sequence of SEQ ID NO:8 or is encoded by the nucleic acid sequence of SEQ ID NO:7.

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44 (depends on 34)

A nucleic acid encoding a base editor according to claim 34.

### Claim 45 (depends on 34)

A system for base-editor-directed repair (BE-mediated correction) of a C202T mutation that produces CD3δ SCID disease, said system comprising:
a base editor according to claim 34, or a nucleic acid encoding a base editor according to claim 34; and
a single-guide RNA (sgRNA) that directs said base editor to the location of the nucleic acids encoding the C202T mutation.

### Claim 46 (depends on 45)

The system of claim 45, wherein said sgRNA comprises the sequence of the G1 (Guide 2T) sgRNA (SEQ ID NO:1) or wherein said sgRNA comprises the sequence of the Guide 5T) sgRNA (SEQ ID NO:2).

### Claim 47

(canceled)

### Claim 48 (depends on 34)

A method of correcting a C202T mutation in a mammalian cell using Adenine Base Editing (ABE)-correction, said method comprising:
introducing a base editor according to claim 34, or a nucleic acid encoding a base editor according to claim 34, and a single-guide RNA (sgRNA) that directs said base editor to the location of the nucleic acids encoding the C202T mutation into said cell; and
culturing said cell to permit base editor (BE) mediated correction of the C202T mutation in said cell to provide a corrected cell, wherein said cell is from a human subject identified as having CD3δ severe combined immunodeficiency (SCID).

### Claim 49

(canceled)

### Claim 50

(canceled)

### Claim 51

(canceled)

### Claim 52

(canceled)

### Claim 53 (depends on 48)

The method according to claim 48, wherein the cell is a stem/progenitor cell, wherein optionally said stem cell is derived from bone marrow and/or from umbilical cord blood and/or from peripheral blood, or said progenitor cell is a human hematopoietic progenitor cell.

### Claim 54

(canceled)

### Claim 55

(canceled)

### Claim 56

(canceled)

### Claim 57

(canceled)

### Claim 58 (depends on 48)

The method according to claim 48, wherein said method further comprises introducing said corrected cell into a subject identified as having CD3δ severe combined immunodeficiency (SCID).

### Claim 59

(canceled)

### Claim 60 (depends on 48)

A method of treating a subject for CD3δ severe combined immunodeficiency (SCID), said method comprising:
providing stem/progenitor cells from said subject;
correcting a C202T mutation in said cells ex vivo using the method according to claim 48 to produce corrected cells; and
introducing said corrected cells into said subject.

### Claim 61

(canceled)

### Claim 62

(canceled)

### Claim 63

(canceled)

### Claim 64

(canceled)

### Claim 65

(canceled)

### Claim 66

A lentivirus for evaluating gene editing correction of the CD3δ SCID-causing C202T mutation, said lentivirus construct comprising the elements illustrated in FIG. 3.

### Claim 67 (depends on 66)

The lentivirus of claim 66, wherein said lentivirus comprises the sequence of SEQ ID NO:1107.
